Inhibitors of PD-1 and PD-L1 have been studied in various tumor types and have now been approved for treating many malignancies, including melanoma, non-small-cell lung cancer (NSCLC), and bladder cancer 12-16. Here, CD274 is linked to non-small cell lung carcinoma.